Celldex Therapeutics heads into its June 25 earnings with short sellers rebuilding positions, UBS lifting its target on the day, and the stock still down sharply from its month-ago levels.
The most telling tension this week is the divergence between short-term price recovery and the medium-term short rebuild. The stock gained 2.4% on the week to $29.60, clawing back ground after a 13% slide in May. But shorts are not retreating — short interest has climbed to 11.1% of the free float, up roughly 4% on the week and now building for a second consecutive week after a period of covering in May. The absolute position peaked near 8.3 million shares in early May before a wave of covering into mid-month; what has followed since late May is a steady, incremental re-accumulation that has brought the position back toward 7.4 million shares. That is meaningful rebuilding pressure in a pre-catalyst window, two weeks out from a scheduled print.
The borrow market tells a less aggressive story, though. Availability is extremely loose — currently around 1,715%, meaning there are roughly seventeen available shares for every one already borrowed. That sits at the low end of recent history but remains well above any squeeze-relevant threshold; the 52-week minimum availability was 528%, so the pool has never come close to being strained. Cost to borrow confirms the same picture: at 0.46%, nudging modestly higher on the week but still running well below one percent. Shorts have the numbers and the cheap borrow to press positions without friction. The ORTEX short score has drifted higher through the week, reaching 56.3 — a two-week high — consistent with an incremental shift in positioning rather than a dramatic rerating. Options add a further layer of caution: the put/call ratio of 1.46 is running near its 20-day average of 1.48, neither elevated nor easing, suggesting options traders are not making a directional call ahead of earnings so much as maintaining a moderately defensive baseline that has been in place since mid-May.
The Street is constructively positioned but with a clear gap between analyst optimism and where the stock trades. UBS this morning raised its target to $45 from $38 while maintaining a Buy, following Wells Fargo's target hike to $54 in mid-May. Barclays, which upgraded sharply from Underweight to Overweight in April with a target jump to $45, raised again to $48 on the May print. The consensus buy rating carries a mean target of $57.53 — implying roughly 94% upside from the current price — which sounds generous but reflects the binary nature of a clinical-stage biotech rather than misplaced analyst exuberance. Goldman Sachs holds a lone Neutral at $34, providing the sceptic's anchor. The bull case rests on barzolvolimab's durability data from the Phase II chronic spontaneous urticaria program and the upcoming readout for the CIndU indication. The bear case is straightforward: clinical trial delays or a disappointing data package would materially reset the stock. Price-to-book of 4.2 is the only conventional valuation anchor that makes sense for a pre-revenue name; EPS and EV/EBITDA multiples are deeply negative and tell you nothing useful about valuation trajectory here.
Institutional ownership reinforces the bull side. Wellington Management holds 10.9% of shares, the largest single position, and added over 585,000 shares in the most recent reporting period. Point72 built a position of 4.1% of shares — adding 1.47 million shares — in the quarter to March. BlackRock and State Street both added modestly through May. The concentration of specialist healthcare funds in the top-15, including Commodore Capital, Eversept Partners, and Deep Track Capital, reflects the kind of high-conviction positioning typical of names trading through a Phase III setup. Insider data is stale beyond the 90-day threshold — the most recent disclosed trade dates to December 2025 — so no fresh signal there.
Earnings history underscores the stock's sensitivity to clinical news flow. The most recent print on May 11 delivered a 5.8% single-day decline and a five-day slide of 11%. February's result went the other way: a 23% gain on the day and 19% over the subsequent five days. The two prints before that added 8% and 30% respectively on a five-day basis. The pattern is not consistent direction — it is consistently large moves, both ways. With the June 25 event now the next focal point, what to watch is whether short sellers continue rebuilding into the release, and what the 44-week CIndU data readout says about barzolvolimab's durability relative to existing market benchmarks.
See the live data behind this article on ORTEX.
Open CLDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
